Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 149

1.

One-Pot Production of RNA Nanoparticles via Automated Processing and Self-Assembly.

Jasinski DL, Binzel DW, Guo P.

ACS Nano. 2019 Apr 23;13(4):4603-4612. doi: 10.1021/acsnano.9b00649. Epub 2019 Mar 22.

PMID:
30888787
2.

The Effect of Size and Shape of RNA Nanoparticles on Biodistribution.

Jasinski DL, Li H, Guo P.

Mol Ther. 2018 Mar 7;26(3):784-792. doi: 10.1016/j.ymthe.2017.12.018. Epub 2017 Dec 22.

3.

The life cycle impact for platinum group metals and lithium to 2070 via surplus cost potential.

Jasiński D, Meredith J, Kirwan K.

Int J Life Cycle Assess. 2018;23(4):773-786. doi: 10.1007/s11367-017-1329-4. Epub 2017 May 11.

4.

RNA nanoparticle distribution and clearance in the eye after subconjunctival injection with and without thermosensitive hydrogels.

Shi Z, Li SK, Charoenputtakun P, Liu CY, Jasinski D, Guo P.

J Control Release. 2018 Jan 28;270:14-22. doi: 10.1016/j.jconrel.2017.11.028. Epub 2017 Nov 21.

5.

Favorable biodistribution, specific targeting and conditional endosomal escape of RNA nanoparticles in cancer therapy.

Xu C, Haque F, Jasinski DL, Binzel DW, Shu D, Guo P.

Cancer Lett. 2018 Feb 1;414:57-70. doi: 10.1016/j.canlet.2017.09.043. Epub 2017 Oct 5. Review.

6.

Using Planar Phi29 pRNA Three-Way Junction to Control Size and Shape of RNA Nanoparticles for Biodistribution Profiling in Mice.

Haque F, Xu C, Jasinski DL, Li H, Guo P.

Methods Mol Biol. 2017;1632:359-380. doi: 10.1007/978-1-4939-7138-1_23.

PMID:
28730451
7.

Evaluation of Thermal Stability of RNA Nanoparticles by Temperature Gradient Gel Electrophoresis (TGGE) in Native Condition.

Benkato K, O'Brien B, Bui MN, Jasinski DL, Guo P, Khisamutdinov EF.

Methods Mol Biol. 2017;1632:123-133. doi: 10.1007/978-1-4939-7138-1_8.

PMID:
28730436
8.

Directional mechanical stability of Bacteriophage φ29 motor's 3WJ-pRNA: Extraordinary robustness along portal axis.

Xu Z, Sun Y, Weber JK, Cao Y, Wang W, Jasinski D, Guo P, Zhou R, Li J.

Sci Adv. 2017 May 26;3(5):e1601684. doi: 10.1126/sciadv.1601684. eCollection 2017 May.

9.

Hydrophobic Effect from Conjugated Chemicals or Drugs on In Vivo Biodistribution of RNA Nanoparticles.

Jasinski DL, Yin H, Li Z, Guo P.

Hum Gene Ther. 2018 Jan;29(1):77-86. doi: 10.1089/hum.2017.054. Epub 2017 Oct 12.

10.

Advancement of the Emerging Field of RNA Nanotechnology.

Jasinski D, Haque F, Binzel DW, Guo P.

ACS Nano. 2017 Feb 28;11(2):1142-1164. doi: 10.1021/acsnano.6b05737. Epub 2017 Feb 7. Review.

11.

Fabrication of RNA 3D Nanoprisms for Loading and Protection of Small RNAs and Model Drugs.

Khisamutdinov EF, Jasinski DL, Li H, Zhang K, Chiu W, Guo P.

Adv Mater. 2016 Dec;28(45):10079-10087. doi: 10.1002/adma.201603180. Epub 2016 Oct 19.

12.

Simple Method for Constructing RNA Triangle, Square, Pentagon by Tuning Interior RNA 3WJ Angle from 60° to 90° or 108°.

Khisamutdinov EF, Bui MN, Jasinski D, Zhao Z, Cui Z, Guo P.

Methods Mol Biol. 2015;1316:181-93. doi: 10.1007/978-1-4939-2730-2_15.

PMID:
25967062
13.

Large scale purification of RNA nanoparticles by preparative ultracentrifugation.

Jasinski DL, Schwartz CT, Haque F, Guo P.

Methods Mol Biol. 2015;1297:67-82. doi: 10.1007/978-1-4939-2562-9_5.

PMID:
25895996
14.

Enhancing immunomodulation on innate immunity by shape transition among RNA triangle, square and pentagon nanovehicles.

Khisamutdinov EF, Li H, Jasinski DL, Chen J, Fu J, Guo P.

Nucleic Acids Res. 2014 Sep;42(15):9996-10004. doi: 10.1093/nar/gku516. Epub 2014 Aug 4.

15.

Physicochemically tunable polyfunctionalized RNA square architecture with fluorogenic and ribozymatic properties.

Jasinski DL, Khisamutdinov EF, Lyubchenko YL, Guo P.

ACS Nano. 2014 Aug 26;8(8):7620-9.

16.

RNA as a boiling-resistant anionic polymer material to build robust structures with defined shape and stoichiometry.

Khisamutdinov EF, Jasinski DL, Guo P.

ACS Nano. 2014 May 27;8(5):4771-81. doi: 10.1021/nn5006254. Epub 2014 Apr 3.

17.

Implementation of a teaching assistant program in graduate nursing education.

Goode VM, Horvath C, Jasinski D.

Nurse Educ. 2013 Sep-Oct;38(5):188-90. doi: 10.1097/NNE.0b013e3182a0e734.

PMID:
23969745
18.

A multisite, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of vigabatrin for treating cocaine dependence.

Somoza EC, Winship D, Gorodetzky CW, Lewis D, Ciraulo DA, Galloway GP, Segal SD, Sheehan M, Roache JD, Bickel WK, Jasinski D, Watson DW, Miller SR, Somoza P, Winhusen T.

JAMA Psychiatry. 2013 Jun;70(6):630-7. doi: 10.1001/jamapsychiatry.2013.872.

PMID:
23575810
19.

Core outcome measures for opioid abuse liability laboratory assessment studies in humans: IMMPACT recommendations.

Comer SD, Zacny JP, Dworkin RH, Turk DC, Bigelow GE, Foltin RW, Jasinski DR, Sellers EM, Adams EH, Balster R, Burke LB, Cerny I, Colucci RD, Cone E, Cowan P, Farrar JT, Haddox JD, Haythornthwaite JA, Hertz S, Jay GW, Johanson CE, Junor R, Katz NP, Klein M, Kopecky EA, Leiderman DB, McDermott MP, O'Brien C, O'Connor AB, Palmer PP, Raja SN, Rappaport BA, Rauschkolb C, Rowbotham MC, Sampaio C, Setnik B, Sokolowska M, Stauffer JW, Walsh SL.

Pain. 2012 Dec;153(12):2315-24. doi: 10.1016/j.pain.2012.07.035. Epub 2012 Sep 19.

20.

Long-term opioid therapy, aberrant behaviors, and substance misuse: comparison of patients treated by resident and attending physicians in a general medical clinic.

Colburn JL, Jasinski DR, Rastegar DA.

J Opioid Manag. 2012 May-Jun;8(3):153-60. doi: 10.5055/jom.2012.0111.

PMID:
22798175
21.

Workplace aggression: assessment of prevalence in the field of nurse anesthesia.

Sakellaropoulos A, Pires J, Estes D, Jasinski D.

AANA J. 2011 Aug;79(4 Suppl):S51-7.

PMID:
22403967
22.

Buprenorphine maintenance treatment in a primary care setting: outcomes at 1 year.

Soeffing JM, Martin LD, Fingerhood MI, Jasinski DR, Rastegar DA.

J Subst Abuse Treat. 2009 Dec;37(4):426-30. doi: 10.1016/j.jsat.2009.05.003. Epub 2009 Jun 23.

PMID:
19553061
23.

Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse.

Jasinski DR, Krishnan S.

J Psychopharmacol. 2009 Jun;23(4):419-27. doi: 10.1177/0269881109103113. Epub 2009 Mar 27.

PMID:
19329547
24.

Human pharmacology of intravenous lisdexamfetamine dimesylate: abuse liability in adult stimulant abusers.

Jasinski DR, Krishnan S.

J Psychopharmacol. 2009 Jun;23(4):410-8. doi: 10.1177/0269881108093841. Epub 2008 Jul 17.

PMID:
18635707
25.

Dosing adjustments in postpartum patients maintained on buprenorphine or methadone.

Jones HE, Johnson RE, O'Grady KE, Jasinski DR, Tuten M, Milio L.

J Addict Med. 2008 Jun;2(2):103-7. doi: 10.1097/ADM.0b013e31815ca2c6.

PMID:
21768979
26.

Abuse liability assessment of atomoxetine in a drug-abusing population.

Jasinski DR, Faries DE, Moore RJ, Schuh LM, Allen AJ.

Drug Alcohol Depend. 2008 May 1;95(1-2):140-6. doi: 10.1016/j.drugalcdep.2008.01.008. Epub 2008 Mar 6.

PMID:
18328639
27.

Buprenorphine and norbuprenorphine in hair of pregnant women and their infants after controlled buprenorphine administration.

Goodwin RS, Wilkins DG, Averin O, Choo RE, Schroeder JR, Jasinski DR, Johnson RE, Jones HE, Huestis MA.

Clin Chem. 2007 Dec;53(12):2136-43. Epub 2007 Oct 5.

28.

Challenges in the development of prescription opioid abuse-deterrent formulations.

Katz NP, Adams EH, Chilcoat H, Colucci RD, Comer SD, Goliber P, Grudzinskas C, Jasinski D, Lande SD, Passik SD, Schnoll SH, Sellers E, Travers D, Weiss R.

Clin J Pain. 2007 Oct;23(8):648-60. Review.

PMID:
17885342
29.

A published student journal: effect on graduate students of nurse anesthesia.

Christ J, Cutler R, Mahrs R, Jasinski D, Pearson J.

AANA J. 2006 Dec;74(6):433-9.

PMID:
17236389
30.

Increased occupancy of dopamine receptors in human striatum during cue-elicited cocaine craving.

Wong DF, Kuwabara H, Schretlen DJ, Bonson KR, Zhou Y, Nandi A, Brasić JR, Kimes AS, Maris MA, Kumar A, Contoreggi C, Links J, Ernst M, Rousset O, Zukin S, Grace AA, Lee JS, Rohde C, Jasinski DR, Gjedde A, London ED.

Neuropsychopharmacology. 2006 Dec;31(12):2716-27. Epub 2006 Sep 13. Erratum in: Neuropsychopharmacology. 2007 Jan;32(1):256. Lee, Jae Sung [added].

31.

Development and preliminary experience with an ease of extractability rating system for prescription opioids.

Katz NP, Buse DC, Budman SH, Wing Venuti S, Fernandez KC, Benoit C, Bianchi R, Cooper D, Jasinski DR, Smith DE, Butler SF.

Drug Dev Ind Pharm. 2006 Jul;32(6):727-46.

PMID:
16885128
32.

Five year outcomes of a cohort of HIV-infected injection drug users in a primary care practice.

Fingerhood M, Rastegar DA, Jasinski D.

J Addict Dis. 2006;25(2):33-8.

PMID:
16785217
33.

Providing smoking cessation counseling: a national survey among nurse anesthetists.

Yankie VM, Price HM, Nanfito ER, Jasinski DM, Crowell NA, Heath J.

Crit Care Nurs Clin North Am. 2006 Mar;18(1):123-9, xiv.

PMID:
16546015
34.
35.
36.

A resident clerkship that combines inpatient and outpatient training in substance abuse and HIV care.

Rastegar DA, Fingerhood MI, Jasinski DR.

Subst Abus. 2004 Dec;25(4):11-5.

PMID:
16172088
37.

Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome.

Jones HE, Johnson RE, Jasinski DR, O'Grady KE, Chisholm CA, Choo RE, Crocetti M, Dudas R, Harrow C, Huestis MA, Jansson LM, Lantz M, Lester BM, Milio L.

Drug Alcohol Depend. 2005 Jul;79(1):1-10.

PMID:
15943939
38.

Randomized controlled study transitioning opioid-dependent pregnant women from short-acting morphine to buprenorphine or methadone.

Jones HE, Johnson RE, Jasinski DR, Milio L.

Drug Alcohol Depend. 2005 Apr 4;78(1):33-8.

PMID:
15769555
40.

Abstinence incentive effects in a short-term outpatient detoxification program.

Katz EC, Chutuape MA, Jones H, Jasinski D, Fingerhood M, Stitzer M.

Exp Clin Psychopharmacol. 2004 Nov;12(4):262-8.

PMID:
15571443
41.

Promoting publication by producing a student journal.

Pearson JA, VanNest RL, Jasinski DM.

Nurse Educ. 2004 Mar-Apr;29(2):68-70. No abstract available.

PMID:
15085007
42.

[Analysis of type 1 diabetes mellitus symptoms at admission to hospital].

Jasiński D, Pilecki O, Robak-Kontna K, Zbikowska-Bojko M.

Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw. 2003;9(2):83-7. Polish.

PMID:
14575617
43.

[Epidemiology of type 1 diabetes mellitus in Bydgoszcz region in the years 1997-2002].

Pilecki O, Robak-Kontna K, Jasiński D, Boguń-Reszczyńska Z, Bojko-Zbikowska M.

Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw. 2003;9(2):77-81. Polish.

PMID:
14575616
44.

Highly active antiretroviral therapy outcomes in a primary care clinic.

Rastegar DA, Fingerhood MI, Jasinski DR.

AIDS Care. 2003 Apr;15(2):231-7.

PMID:
12856344
45.

A Comparison of Clonidine and Buprenorphine in the Outpatient Treatment of Opiate Withdrawal.

Fingerhood MI, Thompson MR, Jasinski DR.

Subst Abus. 2001 Sep;22(3):193-199.

PMID:
12466679
46.

CRNA-conducted research: is it being done?

Cowan C, Vinayak K, Jasinski DM.

AANA J. 2002 Jun;70(3):181-6.

PMID:
12078465
47.

Isopropyl alcohol inhalation: alternative treatment of postoperative nausea and vomiting.

Merritt BA, Okyere CP, Jasinski DM.

Nurs Res. 2002 Mar-Apr;51(2):125-8.

PMID:
11984383
48.

Postoperative pain management: morphine versus ketorolac.

Anthony D, Jasinski DM.

J Perianesth Nurs. 2002 Feb;17(1):30-42. Review.

PMID:
11845422
49.

One-, three-, and six-month outcomes after brief inpatient opioid detoxification.

Chutuape MA, Jasinski DR, Fingerhood MI, Stitzer ML.

Am J Drug Alcohol Abuse. 2001 Feb;27(1):19-44.

PMID:
11373035
50.

Comparison of drug treatment histories of single and multiple drug abusers in detox.

Greberman SB, Jasinski D.

Addict Behav. 2001 Mar-Apr;26(2):285-8.

PMID:
11316384

Supplemental Content

Loading ...
Support Center